AbCellera Biologics Q2 EPS $(0.13) Beats $(0.14) Estimate, Sales $7.32M Miss $10.15M Estimate
Author: Benzinga Newsdesk | August 06, 2024 04:07pm
AbCellera Biologics (NASDAQ:
ABCL) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 18.18 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $7.32 million which missed the analyst consensus estimate of $10.15 million by 27.85 percent. This is a 27.18 percent decrease over sales of $10.06 million the same period last year.
Posted In: ABCL